Haematology 2018

JULIET: Patient characteristics

Baseline characteristics (N=99)

Median time from infusion to DCO, months

5.6

Median age, years ≥65 years, %

56 (range, 22−76) 23

ECOG PS 0/1, %

55/45

Stage III or IV disease, %

77

Double/triplet hits in CMYC / BCL2 / BCL6 genes, %

15

Lymphodepleting chemo prior to infusion, %*

93

Median prior lines antineoplastic therapy, n (range)

3 (1−6) (95% ≥2; 51% ≥3 prior lines therapy)

Bridging therapy, %

90

Prior auto-SCT, %

47

Median dose

3.1 × 10 (range, 0.1−6.0 × 10) CTL019 transduced cells

*Prior to infusion, patients underwent restaging, 93% received lymphodepleting chemotherapy (73% received fludarabine 25 mg/m 2 /cyclophosphamide 250 mg/m 2 /day × 3 days and 19% received bendamustine 90 mg/m 2 /day × 2 days).